

December 20, 2024

Dr. Anne Docimo Chief Medical Officer

Dr. Lucy Langer National Medical Director of Oncology and Genomics

Dr. Donald Tavakoli National Medical Director, Behavioral Health

UnitedHealthcare 5901 Lincoln Drive Saint Louis Park, MN 55436

Delivered electronically

Dear Drs. Docimo, Langer and Tavakoli:

On behalf of the Personalized Medicine Coalition (PMC), a multi-stakeholder group comprising more than 200 institutions and individuals from across the health care spectrum, I am writing regarding UnitedHealthcare (UHC)'s recent revision of its Pharmacogenetic Panel Testing Policy<sup>i</sup>. Since 2019, UHC members have benefited from clinically useful pharmacogenetic (PGx) tests for selecting effective treatments for mental health conditions. Beginning on January 1, 2025, the revised policy would remove longstanding coverage for "multi-gene" PGx panel tests that can help guide patients as efficiently as possible toward effective treatments for major depressive disorder and anxiety and will continue lack of coverage for multi-gene pharmacogenetic panels for other areas of therapy based on the number of genes rather than their clinical utility. This is concerning, and UHC should reconsider implementation.

## **Statement of Neutrality**

Many of PMC's members may present their own responses to UHC's Pharmacogenetic Panel Testing Policy. PMC's comments are designed to provide feedback so that the general concept of personalized medicine can advance and are not intended to adversely impact the ability of individual PMC members, alone or in combination, to pursue separate comments with respect to this policy or related issues.

## Background

PMC defines personalized medicine as a field in which physicians use diagnostic tests and individual details about a person and their health to determine which medical treatments will work best for each patient or use medical interventions to alter molecular mechanisms that impact health. By

Personalized Medicine Coalition personalized medicine coalition.org

1710 Rhode Island Ave., NW, Suite 700 Washington, DC 20036 BOARD OF DIRECTORS

President Edward Abrahams, Ph.D.

Chair Lincoln D. Nadauld, M.D., Ph.D. Culmination Bio

Vice Chair Lauren Silvis, J.D. Tempus

Treasurer Peter Maag, Ph.D.

Secretary Michael S. Sherman, M.D., M.B.A., M.S. RA Capital Management

Gabrielle Allegri, M.B.A. Johnson & Johnson

Antonio L. Andreu, M.D., Ph.D. European Infrastructure for Translational Research (EATRIS)

Dawn Cardeiro, M.S. Roche Diagnostics

Brian Caveney, M.D. Labcorp

William S. Dalton, Ph.D., M.D. Aster Insights

Stephen L. Eck, M.D., Ph.D. MacroGenics

Helmy Eltoukhy, Ph.D. Guardant Health

Lori Frank, Ph.D. Women's Health Access Matters

Sarah Hersey, M.S., M.B.A., R.A.C. Bristol Myers Squibb

*Steffan Ho, M.D., Ph.D.* Pfizer

Richard Knight American Association of Kidney Patients

*James Lillard, Ph.D., M.B.A.* Morehouse School of Medicine

Howard McLeod, Pharm.D. Clarified Precision Medicine

*J. Brian Munroe* Bausch Health Companies

*Elizabeth O'Day, Ph.D.* Olaris, Inc.

Josh Ofman, M.D., M.S.H.S. Grail

Prasanth Reddy, M.D.

*Cecelia Schott, Pharm.D., M.B.A.* GlaxoSmithKline

Apostolia Tsimberidou, M.D., Ph.D. MD Anderson Cancer Center

Michael J. Vasconcelles, M.D.

Jay G. Wohlgemuth, M.D. Genesis BioCapital

P: 202.589.1770 F: 202.589.1778 combining data from diagnostic tests with an individual's medical history, circumstances and values, health care providers can develop targeted treatment and prevention plans with their patients. Personalized medicine is helping to shift patient and provider experiences away from trial-and-error treatment of late-stage diseases in favor of more streamlined approaches to disease prevention and treatment.

Pharmacogenetics is a cornerstone of personalized medicine and holds enormous potential for improving therapeutic decision-making and therapeutic response, as well as decreasing adverse reactions. An analysis of the real-world use of PGx testing and active medication management demonstrated improvements in patient outcomes and lower health care costs.<sup>ii</sup> Randomized trials to date also show a significant reduction in adverse events when multi-gene PGx panels are utilized to guide treatment.<sup>iii</sup> The availability of tests that accurately and reliably identify variations in genes that account for differences in drug response is critical to the success of pharmacogenetics. Where appropriate evidence exists for coverage of such tests, treating providers and the patients they serve should have access to them. UHC had previously been a leader in providing access to PGx panel testing services for its members for major depressive disorder and generalized anxiety disorder. However, sudden revision of the current Pharmacogenetic Panel Testing Policy sets a troublesome precedent.

## **Call for reconsideration**

We are unaware of an example where a commercial payer has rescinded longstanding coverage for a class of tests in the absence of new data indicating harm to patients. PMC is concerned about the loss of patient and provider access resulting from this sudden policy reversal as well as the impact this decision may have on continued investment in personalized medicine. Therefore, we respectfully request that UHC reconsider implementation of this revised policy on January 1, 2025.

Please feel free to contact me at <u>cbens@personalizedmedicinecoalition.org</u> or David Davenport, PMC's Director of Science and Public Policy, at <u>ddavenport@personalizedmedicinecoalition.org</u> with any questions.

Sincerely,

Comthin Berg

Cynthia A. Bens Senior Vice President, Public Policy

1710 Rhode Island Ave., NW, Suite 700P:Washington, DC 20036F:

<sup>&</sup>lt;sup>i</sup> UnitedHealthcare. Commercial and Individual Exchange Medical Policy Pharmacogenetic Panel Testing. <u>https://www.uhcprovider.com/content/dam/provider/docs/public/policies/index/commercial/pharmacogenetic-panel-testing-01012025.pdf</u>

<sup>&</sup>lt;sup>ii</sup> Jarvis, J.P.; Peter, A.P.; Keogh, M.; Baldasare, V.; Beanland, G.M.; Wilkerson, Z.T.; Kradel, S.; Shaman, J.A. Real-World Impact of a Pharmacogenomics-Enriched Comprehensive Medication Management Program. J. Pers. Med. 2022, 12, 421. <u>https://doi.org/10.3390/jpm12030421</u>

<sup>iii</sup> Swen, Jesse JBuunk, Annemarie et al. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. The Lancet, Volume 401, Issue 10374, 347 – 356. <u>https://doi.org/10.1016/S0140-6736(22)01841-4</u>

1710 Rhode Island Ave., NW, Suite 700 Washington, DC 20036 P: 202.589.1770 F: 202.589.1778